Device Trial Radar · NCT07645820
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Apr 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Castle Biosciences IncorporatedNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- SciBase AB
- First posted
- Jun 12, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Conditions
- Atopic Dermatitis
Interventions
Nevisense electrical impedance spectroscopyDevice
The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relationship between skin measurements and subsequent atopic dermatitis flaresTime frame: Measurements taken over 90 days, 5 days a week
- Develop and validate an algorithm using Nevisense Go EISTime frame: From enrollment until end of treatment at 90 days.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
U.S. Dermatology Partners
Phoenix, Arizona · Recruiting
James Y. Wang MD, Inc
Los Angeles, California · Recruiting
True Blue Clinical Research
Tampa, Florida · Recruiting
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.